What You Should Know:
– Helix, a leader in population genomics, is launching new datasets designed to empower life science companies in developing precision medicine therapies.
– These comprehensive datasets, built through collaborations with various health systems, provide researchers with a rich resource for drug discovery and development across multiple disease areas.
Unveiling the Power of Clinico-Genomic Data
The datasets offer a unique combination of longitudinal clinical data and genomic information. This includes extensive medical records spanning a patient’s healthcare journey, along with their genetic makeup. The data covers a wide range of therapeutic areas, including:
- Cardiovascular diseases
- Immunological and inflammatory conditions
- Metabolic disorders
Precision Cohorts for Targeted Research
Helix’s approach leverages “precision cohorts,” meticulously curated groups of patients with specific characteristics. These cohorts combine longitudinal clinical data, such as diagnoses, procedures, lab results, and medications, with genetic information obtained through Helix’s proprietary Exome+® sequencing technology. This comprehensive data is available for over 125,000 consented patients across the US, allowing researchers to target specific patient populations for their studies.
Real-World Data for Real-World Solutions
The datasets are further enhanced by regular updates, ensuring researchers have access to the latest clinical information. This includes structured data from electronic health records (EHRs), providing a detailed picture of a patient’s health. For instance, the Cardiometabolic cohort offers data for over 50,000 patients with cardiovascular disease. This includes patient vitals, demographics, and key lab results like cholesterol and blood sugar levels. Critically, all of this clinical data is linked to a patient’s exome sequencing data, allowing researchers to identify genetic variations that influence disease risk and treatment response.
“Life science researchers can utilize Helix’s diverse clinico-genomic cohorts to better understand genetic factors associated with disease progression and clinical outcomes, as well as validating therapeutic candidates of interest,” said Hylton Kalvaria, Chief Commercial Officer of Helix. “Organizations can also rapidly identify targeted patient populations based on specific genetic and phenotypic criteria to optimize discovery and clinical development.”
